News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
347,231 Results
Type
Article (20789)
Company Profile (128)
Press Release (326314)
Multimedia
Podcasts (73)
Webinars (11)
Section
Business (108713)
Career Advice (885)
Deals (19457)
Drug Delivery (97)
Drug Development (52002)
Employer Resources (79)
FDA (8057)
Job Trends (8020)
News (192035)
Policy (17944)
Tag
Academia (746)
Accelerated approval (3)
Adcomms (17)
Allergies (45)
Alliances (28695)
ALS (55)
Alzheimer's disease (654)
Antibody-drug conjugate (ADC) (96)
Approvals (8079)
Artificial intelligence (147)
Autoimmune disease (16)
Automation (6)
Bankruptcy (178)
Best Places to Work (5717)
BIOSECURE Act (13)
Biosimilars (98)
Biotechnology (57)
Bladder cancer (41)
Brain cancer (19)
Breast cancer (115)
Cancer (1139)
Cardiovascular disease (117)
Career advice (719)
Career pathing (21)
CAR-T (56)
Cell therapy (167)
Cervical cancer (5)
Clinical research (43790)
Collaboration (496)
Compensation (185)
Complete response letters (23)
COVID-19 (1113)
CRISPR (24)
C-suite (161)
Cystic fibrosis (58)
Data (1225)
Decentralized trials (2)
Denatured (18)
Depression (28)
Diabetes (153)
Diagnostics (1911)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (82)
Drug pricing (112)
Drug shortages (30)
Duchenne muscular dystrophy (61)
Earnings (40701)
Editorial (32)
Employer branding (10)
Employer resources (73)
Events (50349)
Executive appointments (476)
FDA (8707)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (324)
Gene editing (49)
Generative AI (18)
Gene therapy (149)
GLP-1 (606)
Government (1881)
Grass and pollen (3)
Guidances (29)
Healthcare (6087)
Huntington's disease (13)
IgA nephropathy (21)
Immunology and inflammation (88)
Indications (20)
Infectious disease (1199)
Inflammatory bowel disease (85)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (59)
Interviews (116)
IPO (7707)
IRA (45)
Job creations (2546)
Job search strategy (652)
Kidney cancer (7)
Labor market (24)
Layoffs (281)
Leadership (16)
Legal (4341)
Liver cancer (33)
Lung cancer (171)
Lymphoma (91)
Machine learning (3)
Management (30)
Manufacturing (220)
MASH (52)
Medical device (2290)
Medtech (2293)
Mergers & acquisitions (12033)
Metabolic disorders (523)
Multiple sclerosis (50)
NASH (20)
Neurodegenerative disease (50)
Neuropsychiatric disorders (23)
Neuroscience (989)
NextGen: Class of 2025 (2384)
Non-profit (919)
Now hiring (23)
Obesity (324)
Opinion (191)
Ovarian cancer (37)
Pain (71)
Pancreatic cancer (39)
Parkinson's disease (89)
Partnered (12)
Patents (150)
Patient recruitment (50)
Peanut (17)
People (34422)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13654)
Phase II (18484)
Phase III (14905)
Pipeline (781)
Policy (127)
Postmarket research (1735)
Preclinical (4776)
Press Release (29)
Prostate cancer (66)
Psychedelics (16)
Radiopharmaceuticals (165)
Rare diseases (248)
Real estate (3240)
Recruiting (29)
Regulatory (12954)
Reports (24)
Research institute (835)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (29)
Schizophrenia (63)
Series A (59)
Series B (34)
Service/supplier (7)
Sickle cell disease (36)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2056)
State (2)
Stomach cancer (9)
Supply chain (55)
Tariffs (44)
The Weekly (53)
Vaccines (290)
Venture capitalists (29)
Weight loss (245)
Women's health (14)
Worklife (8)
Date
Today (72)
Last 7 days (442)
Last 30 days (1320)
Last 365 days (17059)
2025 (5668)
2024 (18095)
2023 (20193)
2022 (27105)
2021 (28080)
2020 (26122)
2019 (20693)
2018 (15947)
2017 (17922)
2016 (16768)
2015 (19590)
2014 (15428)
2013 (13025)
2012 (14028)
2011 (14295)
2010 (13191)
Location
Africa (416)
Alabama (23)
Alaska (1)
Arizona (68)
Arkansas (8)
Asia (25193)
Australia (3264)
California (2671)
Canada (1145)
China (345)
Colorado (105)
Connecticut (102)
Delaware (78)
Europe (58929)
Florida (467)
Georgia (56)
Idaho (16)
Illinois (262)
India (20)
Indiana (177)
Iowa (4)
Japan (128)
Kansas (64)
Kentucky (18)
Louisiana (2)
Maine (4)
Maryland (390)
Massachusetts (2284)
Michigan (48)
Minnesota (140)
Mississippi (1)
Missouri (28)
Montana (10)
Nebraska (12)
Nevada (19)
New Hampshire (8)
New Jersey (1073)
New Mexico (21)
New York (800)
North Carolina (525)
North Dakota (2)
Northern California (1130)
Ohio (85)
Oklahoma (5)
Oregon (22)
Pennsylvania (674)
Puerto Rico (12)
Rhode Island (18)
South America (623)
South Carolina (3)
Southern California (1098)
Tennessee (38)
Texas (347)
United States (10750)
Utah (57)
Virginia (91)
Washington D.C. (45)
Washington State (235)
Wisconsin (23)
347,231 Results for "midatech pharma plc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Midatech Pharma PLC Announces Results of General Meeting
Midatech Pharma PLC is pleased to announce that at the general meeting of the Company held earlier today all resolutions put to the Company’s shareholders were duly passed.
March 24, 2023
·
6 min read
Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease
Midatech Pharma PLC is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.
March 27, 2023
·
6 min read
Pharm Country
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
BIOASIS TECHNOLOGIES INC today announced that it has terminated the arrangement agreement (the “Arrangement Agreement”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“Midatech”).
January 23, 2023
·
4 min read
Midatech Pharma PLC Announces Result of General Meeting
Midatech Pharma PLC announces that at its General Meeting held at 10.00 a.m. today all ordinary resolutions were carried, but all other resolutions were not passed by shareholders, as set out in the table below.
January 23, 2023
·
7 min read
Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting
Midatech Pharma PLC announces, further to the Company’s announcements of 13 December and 19 December 2022, that a circular and Notice of General Meeting was posted to shareholders yesterday.
January 6, 2023
·
7 min read
Business
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
BIOASIS TECHNOLOGIES INC. today announced the following amendments to the terms of the previously announcement arrangement agreement with Midatech Pharma plc.
December 19, 2022
·
4 min read
Midatech Pharma PLC Announces Receipt of NASDAQ Notice - February 03, 2023
Midatech Pharma PLC announces that it received written notification from The NASDAQ Stock Market LLC, dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ’s rules for continued listing on The NASDAQ Capital Market.
February 3, 2023
·
6 min read
Midatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker Change
Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the closing of the Private Placement of 10,344,822 Units initially at an issue price of US$0.58 per Unit.
February 15, 2023
·
6 min read
Press Releases
Hemogenyx Pharmaceuticals PLC Announces Final Results
April 29, 2025
·
1 min read
Drug Development
Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study
Midatech Pharma PLC is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma will continue with a planned dose escalation following a positive recommendation from the study’s Data Safety Monitoring Board.
January 12, 2023
·
8 min read
1 of 34,724
Next
